Follow us on Twitter
twitter icon@FreshPatents

Codon patents

Bulk PDF Downloads
      

This page is updated frequently with new Codon-related patent applications.




 Method for producing peptide library, peptide library, and screening method patent thumbnailnew patent Method for producing peptide library, peptide library, and screening method
An object of the present invention is to provide a method for producing a peptide library capable of incorporating an arbitrary number of arbitrary proteinogenic and/or non-proteinogenic amino acids in an arbitrary site. The invention provides a method for producing a peptide library including 1×106 or more kinds of peptides containing amino acids encoded by n1n2n3, including a step of preparing an mrna library including mrnas which encode peptides of the peptide library and each contain at least one n1n2n3; and a step of translating each mrna of the mrna library in a cell-free translation system added with trna containing an anticodon to any one of n1n2n3 codons and charged with an amino acid corresponding to the codon (wherein, n1, n2, and n3 are each independently selected from adenine (a), guanine (g), cytosine (c), and uracil (u) and an arbitrary amino acid is reassigned to each n1n2n3)..
Peptidream Inc.


 Herbal composition and  use patent thumbnailnew patent Herbal composition and use
The present invention provides herbal compositions comprise radix dioscoreae, radix codonopsis, and radix astragalus membranaceus. The herbal compositions are used to suppress intestinal glucose uptake of intestinal villus and decrease blood glucose levels.

 Process for preparing oxycodone compositions patent thumbnailProcess for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


 Treating pain in patients with hepatic impairment patent thumbnailTreating pain in patients with hepatic impairment
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited


 Method and device for optimizing a nucelotide sequence for the purpose of expression in a protein patent thumbnailMethod and device for optimizing a nucelotide sequence for the purpose of expression in a protein
The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps.
Thermo Fisher Scientific Geneart Gmbh


 Peptide inhibitor of hiv reverse transcription patent thumbnailPeptide inhibitor of hiv reverse transcription
Disclosed are peptides that exhibit good binding to the anticodon stem and loop (asl) of human lysine trna species, trnalys3. Using a search algorithm combining monte carlo (mc) and self-consistent mean field (scmf) techniques, the peptides were evolved a with the ultimate purpose of using them to break the replication cycle of hiv-1 virus.
The Research Foundation For The State University Of New York


 Treating pain in patients with hepatic impairment patent thumbnailTreating pain in patients with hepatic impairment
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited


 Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer patent thumbnailOral dosage forms for oxygen-containing active agents and oxyl-containing polymer
The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, a tri-oxy active agent, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts.
Spriaso Llc


 Process for preparing oxycodone compositions patent thumbnailProcess for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


 Process for preparing oxycodone compositions patent thumbnailProcess for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited


Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


Opioid ketal compounds and uses thereof


This invention relates to opioid ketal compounds of formula (i), formula (ii), or formula (iii): or a pharmaceutically acceptable salts thereof, wherein r1 is h or ch3, r2 is h or oh, n is 0, 1, 2 or 3, r3 and r4 are independently h or optionally substituted c1-c4 alkyl, or when n is 0, then r3 and r4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by c1-c4 alkyl. The invention also relates to oxycodone ketal compounds of formula (iv) or (v): or a pharmaceutically acceptable salts thereof.
Rhodes Technologies


Recombinant peptide vaccines against ticks, and nucleotide sequences coding for the recombinant peptides


The present invention relates to the field of biotechnology and genetic engineering, and particularly to the expression of recombinant peptides. The inoculation thereof in cattle results in the production of an immune response capable of adversely affecting rhipicephalus microplus ticks, which feed on the inoculated cattle, decreasing the number and reproductive capacity of this tick species.
Patsos Endustria E Comercio De Produtos BiotecnolÓgicos Ltda


Recombinant cells and organisms having persistent nonstandard amino acid dependence and methods of making them


Novel recombinant cells and recombinant organisms persistently expressing nonstandard amino acids (nsaas) are provided. Methods of making novel recombinant cells and recombinant organisms dependent on persistently expressing nsaas for survival are also provided.
President And Fellows Of Harvard College


Mice that produce antigen-binding proteins with ph-dependent binding characteristics


Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
Regeneron Pharmaceuticals, Inc.


Controlled release hydrocodone formulations


A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Micronized opioid compositions, formulations and dosage forms and methods of making same


Novel compositions, formulations and dosage forms comprising stabilized micronizedopioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts.
Pain Therapeutics, Inc.


Compositions and methods for the identification of inhibitors of retroviral infection


Methods of identifying inhibitors of retroviral propagation, trna used in the methods, and kits, including the trna, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed.
Trana Discovery, Inc.


Live bacterial vectors for prophylaxis or treatment


A live bacterium, having a dna construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation.
Aviex Technologies Llc


Plants with an intense fruit phenotype


The present invention relates to plants comprising a modified amount, activity or function of agl11-like protein, wherein the plant is a member of plant family cucurbitaceae or of species solanum lycopersicum; characterized in that the plant is not a solanum lycopersicum plant having a deletion from nucleotide 1042 to nucleotide 637 upstream of the atg start codon of seq id no: 1.. .
Nunhems B.v.


Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof


The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.


Modified hepatitis post-transcriptional regulatory elements


Provided are polynucleotides containing a modified pre having a variant x gene that includes one or more stop codons not present in an unmodified, such as wild-type, hepatitis x gene. Also provided are polynucleotides containing a modified pre having a variant x gene that includes one or more degradation sequences not present in an unmodified, such as wild-type, hepatitis x gene.
Juno Therapeutics, Inc.


Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof


The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.


Codon-optimized gene for mutated shrimp luciferase and use thereof


There has been a demand for a codon-optimized gene for the mutated catalytic domain of oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kda protein.

Site-specific incorporation of phosphoserine into proteins in escherichia coli


Nucleic acids encoding mutant elongation factor proteins (ef-sep), phosphoseryl-trna synthetase (seprs), and phosphoseryl-trna (trnasep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, seprs preferentially aminoacylates trnasep with o-phosphoserine and the trnasep recognizes at least one codon such as a stop codon.

Methods for altering polypeptide expression and solubility


The invention is directed to methods and metric suitable for use in determining the solubility, expression and usability of a polypeptide encoded by a nucleic acid sequence. In certain aspects, the invention also relates to methods for introducing modifications in a polypeptide, for example through substitution of one or more codons in the nucleic acid sequence encoding the polypeptide, to increase or decrease the solubility, expression or usability of the polypeptide..

Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia


The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..

A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation


The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in patients suffering from i) pain and at least one further disease ii), wherein said at least one further disease ii) results in intestinal dysbiosis, or for use in the treatment of pain in patients suffering from i) pain and at least one further disease iii), wherein said at least one further disease iii) increases the risk for intestinal bacterial translocation and thus for peritonitis, sirs and/or sepsis.. .

Heterologous expression of termite cellulases in yeast


The present invention provides for heterologous expression of termite and termite-associated symbiont cellulases. The cellulases can, for example, be codon-optimized and expressed in yeast host cells, such as the yeast saccharomyces cerevisiae.

Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Process for preparing oxycodone docage form


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Methods of treating pain


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Oxycodone dosage forms


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

Encoding text into nucleic acid


Methods and apparatus are disclosed herein for encoding human readable text conveying a non-genetic message into nucleic acid sequences with a substantially reduced probability of biological impact and decoding such text from nucleic acid sequences. In one embodiment, each symbol of a symbol set of human readable symbols uniquely maps to a respective codon identifier.
Synthetic Genomics, Inc.


Certain improved human bispecific egfrviii antibody engaging molecules


We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human egfrviii mutant protein on its surface, and a second arm that specifically engages t cell activation ligand cd3. The polynucleotide is codon optimized for expression in cho cells.
The Government Of The U.s. As Represented By The Secretary Of Health


Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof


The presently described technology provides compositions comprising aryl carboxylic acids and, for example nsaids, chemically conjugated to oxycodone (4,5-α-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.


Computationally optimized broadly reactive antigens for h1n1 influenza


Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2012.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.




Codon topics:
  • Hydrocodone
  • Nucleic Acid
  • Acetaminophen
  • Carboxylic Acid
  • Benzoic Acid
  • Genetically
  • Recombinant
  • Amino Acid
  • Nucleotide
  • Reverse Transcriptase Inhibitors
  • Reverse Transcriptase Inhibitor
  • Reverse Transcriptase
  • Antibodies
  • Base Sequence
  • Replication


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.6498

    4469

    0 - 1 - 103